Select Publications

Click title to access publication

Pridopidine does not significantly prolong the QTc interval at the clinically relevant therapeutic dose

Darpo B, Geva M, Ferber G, et al. Neurol Ther. 2023;12(2)597-617. doi:10.1007/s40120-023-00449-w

Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine

Wang SM, Wu HE, Yasui Y, et al. Autophagy. 2023;19(1):126-151. doi:10.1080/15548627.2022.2063003

Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model

Lenoir S, Lahaye RA, Vitet H, et al. Neurobiol Dis. 2022;173:10585. doi:10.1016/j.nbd.2022.105857

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma

Geva M, Gershoni-Emek N, Naia L, et al. Sci Rep. 2021;11(1):21975. doi:10.1038/s41598-021-01077-w

Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the sigma-1 receptor

Shenkman M, Geva M, Gershoni-Emek N, et al. J Neurochem. 2021;158(2):467-481. doi:10.1111/jnc.1536

Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases

Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Int J Mol Sci. 2021;22(8):4082. doi:10.3390/ijms22084082

The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models

Naia L, Ly P, Mota SI, et al. Neurotherapeutics. 2021;18(2):1017-1038. doi:10.1007/s13311-021-01022-9

Effects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD study

McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. J Huntingtons Dis. 2020;9(4):371-380. doi:10.3233/JHD-200440

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study

Grachev ID, Meyer PM, Becker GA, et al. Eur J Nucl Med Mol Imaging. 2021;48(4):1103-1115. doi:10.1007/s00259-020-05030-3

Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease

McGarry A, Auinger P, Kieburtz K, et al. J Huntingtons Dis. 2020;9(2):173-184. doi:10.3233/JHD-190393

Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor

Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Neurobiol Dis. 2019;129:118-129. doi:10.1016/j.nbd.2019.05.009

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques

Johnston TH, Geva M, Steiner L, et al. Mov Disord. 2019;34(5):708-716. doi:10.1002/mds.27565

Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease

Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Front Cell Neurosci. 2019;13:209. doi:10.3389/fncel.2019.00209

Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model

Ionescu A, Gradus T, Altman T, et al. Cell Death Dis. 2019;10(3):210. doi:10.1038/s41419-019-1451-2

Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of Parkinson’s disease

Francardo V, Geva M, Bez F, et al. Neurotherapeutics. 2019;16(2):465-479. doi:10.1007/s13311-018-00699-9

Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Reilmann R, McGarry A, Grachev ID, et al; European Huntington’s Disease Network; Huntington Study Group investigators.. Lancet Neurol. 2019;18(2):165-176. doi:10.1016/S1474-4422(18)30391-0

Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor

Ryskamp D, Wu L, Wu J, et al. Neurobiol Dis. 2019;124:489-504. doi:10.1016/j.nbd.2018.12.022

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Garcia-Miralles M, Geva M, Tan JY, et al. JCI Insight. 2017;2(23):e95665. doi:10.1172/jci.insight.95665

The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease

Ryskamp D, Wu J, Geva M, et al. Neurobiol Dis. 2017;97(pt A):46-59. doi:10.1016/j.nbd.2016.10.006

Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Geva M, Kusko R, Soares H, et al. Hum Mol Genet. 2016;25(18):3975-3987. doi:10.1093/hmg/ddw2

Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

Garcia J, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker R, Saft C, Magnet M, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators. Lancet Neurology. 2011; Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2